CeriBell (NASDAQ:CBLL) Receives Consensus Rating of “Buy” from Brokerages

Shares of CeriBell (NASDAQ:CBLL) have received an average rating of “Buy” from the six research firms that are covering the company, MarketBeat reports. Six research analysts have rated the stock with a buy rating. The average twelve-month price target among analysts that have covered the stock in the last year is $32.60.

Several research analysts have recently weighed in on CBLL shares. William Blair started coverage on shares of CeriBell in a research report on Tuesday, November 5th. They issued an “outperform” rating on the stock. TD Cowen lifted their price objective on shares of CeriBell from $31.00 to $36.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. Canaccord Genuity Group increased their target price on CeriBell from $31.00 to $33.00 and gave the company a “buy” rating in a report on Monday, December 9th. Bank of America initiated coverage on CeriBell in a research report on Tuesday, November 5th. They issued a “buy” rating and a $32.00 target price for the company. Finally, Canaccord Genuity Group began coverage on CeriBell in a research report on Tuesday, November 5th. They set a “buy” rating and a $30.00 price target on the stock.

CeriBell Trading Up 2.2 %

Shares of CeriBell stock opened at $22.32 on Thursday. CeriBell has a 12-month low of $18.69 and a 12-month high of $32.75. The stock’s fifty day moving average is $24.52.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($1.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($1.03). The company had revenue of $17.20 million during the quarter, compared to analysts’ expectations of $17.06 million. Equities research analysts predict that CeriBell will post -2.46 EPS for the current fiscal year.

Institutional Trading of CeriBell

Several hedge funds and other institutional investors have recently modified their holdings of the company. PNC Financial Services Group Inc. purchased a new position in CeriBell in the fourth quarter valued at about $47,000. Corebridge Financial Inc. acquired a new stake in shares of CeriBell during the 4th quarter valued at about $158,000. Wells Fargo & Company MN bought a new stake in shares of CeriBell in the 4th quarter valued at approximately $167,000. Rhumbline Advisers acquired a new position in CeriBell in the fourth quarter worth approximately $320,000. Finally, Norges Bank bought a new position in CeriBell during the fourth quarter valued at approximately $422,000.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.